In a meeting Tuesday, the Prostate Cancer Study Committee heard the final recommendations on how to fight prostate cancer in South Carolina.

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, researchers found in a clinical trial.

Prostate cancer overtook breast cancer as the most commonly diagnosed cancer in England earlier this year. NHS data examined by Prostate Cancer UK revealed that 50,751 men were diagnosed with prostate cancer in 2022,

The phase 3 PSMAddition trial demonstrated that the radioligand therapy Lutetium-177 PSMA-617 (Pluvicto) provides a statistically significant and clinically meaningful benefit when added to standard of care (SOC) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC).

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide and leuprolide,